As a 16-year veteran of GCI Health, Jill represents a rare level of commitment and passion for what she does.  Ask her about the emerging trends facing the healthcare industry and you will see what it means to truly know your subject matter and how to communicate it with contagious energy and simplicity.  A member of the New York State Bar and the Food & Drug Law Institute, Jill provides ongoing counsel to clients and account teams on regulatory and compliance matters.  She brings sharp analytical skills and keen interest in evidence-based medicine to challenges in the oncology, biotechnology, psychiatric, cardiovascular, and CNS arenas and excels at communicating technical, high-science information in ways that resonate with a variety of audiences.  
Jill has led pre and post-approval strategies for numerous clients including Genentech, ImClone, and Sanofi-Aventis, has reintroduced old drugs with new uses, has led campaigns to protect a blockbuster brand from increasing competition and has provided crisis management counsel to healthcare companies and providers in the national spotlight.  Jill currently provides strategic counsel for Biogen Idec’s TYSABRI and MS pipeline products and Boehringer Ingelheim’s HIV and CV franchises.